Primed for toxicity: CD4+ T cells and immune checkpoint inhibitors
- PMID: 35590189
- DOI: 10.1016/j.medj.2022.02.003
Primed for toxicity: CD4+ T cells and immune checkpoint inhibitors
Abstract
Immune-related adverse events (irAEs) occur in almost every organ system in a seemingly unpredictable fashion, causing substantial morbidity and mortality. Lozano et al.1 report peripheral blood profiling from patients receiving immune checkpoint inhibitors, identifying that diverse CD4+ effector memory T cells present prior to treatment are associated with severe irAEs.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests D.B.J. has served on advisory boards or as a consultant for BMS, Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer, and Targovax and has received research funding from BMS and Incyte. J.M.B. receives research support from Genentech/Roche and Incyte Corporation and is an inventor on provisional patents regarding immunotherapy targets and biomarkers in cancer.
Comment on
-
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.Nat Med. 2022 Feb;28(2):353-362. doi: 10.1038/s41591-021-01623-z. Epub 2022 Jan 13. Nat Med. 2022. PMID: 35027754 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials